Immuneering (IMRX) Common Equity (2020 - 2024)
Historic Common Equity for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $57.7 million.
- Immuneering's Common Equity fell 4450.86% to $57.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $57.7 million, marking a year-over-year decrease of 4450.86%. This contributed to the annual value of $90.6 million for FY2023, which is 1754.58% down from last year.
- Per Immuneering's latest filing, its Common Equity stood at $57.7 million for Q3 2024, which was down 4450.86% from $66.3 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Common Equity registered a high of $158.3 million during Q3 2021, and its lowest value of -$35.2 million during Q2 2021.
- Its 5-year average for Common Equity is $91.7 million, with a median of $104.0 million in 2023.
- In the last 5 years, Immuneering's Common Equity soared by 79381.69% in 2021 and then tumbled by 4450.86% in 2024.
- Quarter analysis of 5 years shows Immuneering's Common Equity stood at -$22.5 million in 2020, then surged by 793.82% to $156.0 million in 2021, then decreased by 29.57% to $109.9 million in 2022, then fell by 17.55% to $90.6 million in 2023, then tumbled by 36.27% to $57.7 million in 2024.
- Its last three reported values are $57.7 million in Q3 2024, $66.3 million for Q2 2024, and $78.7 million during Q1 2024.